Results 171 to 180 of about 10,605 (184)

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2011
Klaus F Rabe, Marc Humbert
exaly  

Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence

Clinical Reviews in Allergy and Immunology, 2020
Martin Metz, Emek Kocatürk
exaly  

Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils

Journal of Allergy and Clinical Immunology, 2004
Thomas Casale, Calman Prussin, Barbara Foster   +2 more
exaly  

Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents

Pediatric Allergy and Immunology, 2015
Gustavo J Rodrigo
exaly  

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

Journal of Allergy and Clinical Immunology, 2007
Lawrence Schwartz, Linda Cox
exaly  

Factors reducing omalizumab response in severe asthma

European Journal of Internal Medicine, 2018
Carlo Cavaliere, Alessandro Perrella, A Cresti   +2 more
exaly  

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study

Journal of Allergy and Clinical Immunology: in Practice, 2019
Robert S. Zeiger, Thomas Casale, William W Busse   +2 more
exaly  

Individually dosed omalizumab: an effective treatment for severe peanut allergy

Clinical and Experimental Allergy, 2017
G Lilja, S G O Johansson
exaly  

Omalizumab in the treatment of eosinophilic granulomatosis with polyangiitis (EGPA): single-center experience in 18 cases

World Allergy Organization Journal, 2018
Dilşad Mungan, Ömür Aydın, Zeynep Celebi Sozener   +2 more
exaly  

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

Journal of Allergy and Clinical Immunology, 2001
William W Busse, Niroo Gupta
exaly